Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study

Background A recent large real-world study conducted in the United States reported the effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2− advanced breast cancer (ABC). However, local clinical practice and available medical treatment can vary between Japan and Western countries. Thus,...

Full description

Bibliographic Details

Published in:	Breast cancer (Tokyo, Japan) Vol. 31; no. 4; pp. 621 - 632
Main Authors:	Yoshinami, Tetsuhiro, Nagai, Shigenori E., Hattori, Masaya, Okamura, Takuho, Watanabe, Kenichi, Nakayama, Takahiro, Masuda, Hiroko, Tsuneizumi, Michiko, Takabatake, Daisuke, Harao, Michiko, Yoshino, Hiroshi, Mori, Natsuko, Yasojima, Hiroyuki, Oshiro, Chiya, Iwase, Madoka, Yamaguchi, Miki, Sangai, Takafumi, Kosaka, Nobuyoshi, Tajima, Kentaro, Masuda, Norikazu
Format:	Journal Article
Language:	English
Published:	Singapore Springer Nature Singapore 01-07-2024
Subjects:	Cancer Research Medicine Medicine & Public Health Oncology Original Original Article Surgery Surgical Oncology Advanced breast cancer CDK4/6 inhibitors Palbociclib Real-world evidence
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!